These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 17369566)

  • 1. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
    Cai T; Bartoletti R
    J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual zoledronic acid: is less more?
    Higano CS
    J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
    [No Abstract]   [Full Text] [Related]  

  • 5. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
    Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
    Wadhwa VK; Weston R; Parr NJ
    BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study.
    Rodrigues P; Meler A; Hering F
    Urol Int; 2010; 85(2):180-5. PubMed ID: 20628233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
    N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
    Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.
    Smith MR; Fallon MA; Lee H; Finkelstein JS
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3841-6. PubMed ID: 15292315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.
    Kachnic LA; Pugh SL; Tai P; Smith M; Gore E; Shah AB; Martin AG; Kim HE; Nabid A; Lawton CA
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):382-6. PubMed ID: 24080992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
    Denham JW; Nowitz M; Joseph D; Duchesne G; Spry NA; Lamb DS; Matthews J; Turner S; Atkinson C; Tai KH; Gogna NK; Kenny L; Diamond T; Smart R; Rowan D; Moscato P; Vimieiro R; Woodfield R; Lynch K; Delahunt B; Murray J; D'Este C; McElduff P; Steigler A; Kautto A; Ball J
    BJU Int; 2014 Sep; 114(3):344-53. PubMed ID: 24512527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
    J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.